Reasonable Agreements Between Patient Advocates And Pharmaceutical Companies

Based on the guiding principles, this project has developed four reference agreements for use in different patient communities, including: MSAW represents all THE partners of the RAPP project with legal expertise from patient representatives and pharmaceutical companies. The two working groups provided several rounds of review and feedback throughout the project, as well as ideas and advice on all documents developed. Legal experts have participated in Bayer, Bristol-Myers Squibb, Celgene, Janssen, Merck MSD, Novartis, Novo Nordisk, Pfizer, Roche, Servier, Takeda. Cooperation between pharmaceutical companies and patient lawyers often requires both parties to sign contracts that can often contain very long, difficult-to-understand and ambiguous clauses. In order to be a resource for the legal parties responsible for developing agreements with patient lawyers, four reference agreements have been released for use in different representations of the patient community, such as advisory boards. B, collaborations, speaking commitments and advice. The guiding principles are the result of the consensual work of experts from MPE, WECAN and PFMD patients, as well as legal experts from pharmaceutical companies AMGEN, Bayer, Bristol-Myers Squibb, Celgene, Janssen, MSD, Novartis, Novo Nordisk, Pfizer, Roche, Servier and Takeda. The members of the working group contributed to the design process, discussed areas of compromise and non-consequential issues, and acted as auditors in several review cycles throughout their development. These agreements are jointly developed to align with the guiding principles previously published as part of the multi-party Reasonable Agreements between patients advocates and pharmaceutical companies (RAPP) – a project of the European Cancer Patient Advocacy Networks (WECAN) working group, coordinated by Myeloma Patients Europe (MPE) in collaboration with Patient Focus Focus Medicines Development (PFMD) and the independent participation of more than 10 pharmaceutical companies. These include regular conference calls to discuss implementation issues and opportunities to use the multi-party group and to maintain the project`s ambition to maintain a constructive legal framework and contractual relationships between the parties.

The patient community strongly encourages pharmaceutical partners in the RAPP project and beyond to highlight this initiative and resources for local and European trade associations. Improved legal agreements between patient lawyers and pharmaceutical companies, while ensuring adequate protection and rules for both parties, .@JanssenGlobal contributed to the first edition of the Best Practices book with an inspiring #patientengagement initiative (see t.co/ND0YSxKLNp). Please present your contribution for the 3rd edition 🔜 Now: t.co/X9W7nAw3tZ pic.twitter.com/WNQYbygBWg The project includes representatives from 35 patient associations, 16 pharmaceutical companies and 7 other project partners. The project aims to make the legal relationship between patient lawyers and pharmaceutical companies simpler and more acceptable, while preserving the independence and interests of all parties involved. Each section discusses the justifications, examples and guiding principles of legal agreements between pharmaceutical companies and patient lawyers The project aims to streamline the legal framework between the patient community and the pharmaceutical industry by providing guidelines on the content of legal contracts, while preserving appropriate safeguards for both parties. The joint initiative contributed to the guiding principles for reasonable agreements between patient lawyers and pharmaceutical companies and resulted in the development of four reference agreements for different types of commitments (advisory advice, collaborations, speaking commitments and advice), which are consistent with the guiding principles.

Please follow and like us: